Gilead Sciences, Inc. (GILD) NASDAQ

115.66

+2.0835(+1.83%)

Updated at October 07 03:38PM

Currency In USD

Gilead Sciences, Inc.

Address

333 Lakeside Drive

Foster City, CA 94404

United States of America

Phone

650 574 3000

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

17600

First IPO Date

January 22, 1992

Key Executives

NameTitlePayYear Born
Mr. Daniel P. O'DayChairman & Chief Executive Officer7.14M1965
Mr. Andrew D. DickinsonChief Financial Officer2.73M1970
Ms. Deborah H. Telman J.D.Executive Vice President of Corporate Affairs, General Counsel & Corporate Secretary3.11M1965
Ms. Johanna MercierChief Commercial Officer3.17M1970
Ms. Jacquie Ross C.F.A.Vice President of Investor Relations0N/A
Dr. Linda Slanec Higgins Ph.D.Senior Vice President of Research, Innovation & Portfolio01962
Dr. Flavius Martin M.D.Executive Vice President of Research0N/A
Ms. Diane E. WilfongInterim Corporate Controller, Chief Accounting Officer & Principal Accounting Officer01962
Ms. Jyoti K. MehraExecutive Vice President of Human Resources01977
Dr. Rudolf ErtlSenior Vice President of Commercial Operations of Australia, Canada, Europe01946

Description

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.